Accretion Nutraveda share price & results
- Mar 2026
- Jun 2026
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.5 | +80.1% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 18.2 | −5.6 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.7 | +56.4% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
| Return on equity | −56.5 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | -46.00 | −26.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | −109.4 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance +42.2% YTD
YTD: ₹191.2 on 4 Feb 2026 → ₹271.8. High ₹313 (24 Aug 2026), low ₹155.9 (11 Feb 2026).
- Previous close
- ₹273.25
- Market cap
- ₹197 Cr
- 52-week range
- ₹155.9 – ₹313
- Price to earnings (FY ending Mar 2026)
- 38.86×
- Return on equity (FY ending Mar 2026)
- 25.02%
Overview
- Symbol
- NSE:ANL
- Exchange
- NSE
- Currency
- INR
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 4 fiscal years held (Mar 2023 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +56% (quarter to mar 2026 against mar 2025).
| Line item | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 11 | 14 | 20 |
| Expenses | 8 | 11 | 16 |
| Operating profit | 3 | 3 | 4 |
| Operating margin | 23.8% | 23.5% | 18.2% |
| Other income | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 3 |
| Tax rate | 22.2% | 18.5% | 18.5% |
| Net profit | 2 | 2 | 3 |
| EPS (₹ per share) | 35.32 | 4.38 | 3.72 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 5 | 7 |
| Reserves | -0 | 1 | 5 | 3 | 28 |
| Borrowings | 2 | 2 | 4 | 4 | 4 |
| Other liabilities | 2 | 1 | 2 | 4 | 2 |
| Total liabilities | 4 | 5 | 11 | 16 | 42 |
| Fixed assets | 1 | 1 | 2 | 2 | 2 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other assets | 3 | 3 | 9 | 14 | 40 |
| Total assets | 4 | 5 | 11 | 16 | 42 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 1 | 0 | -2 | -9 |
| Cash from investing | -0 | -0 | -1 | -14 |
| Cash from financing | -1 | -0 | 3 | 25 |
| Net cash flow | 0 | 0 | -0 | 1 |
| Free cash flow | 1 | 0 | -3 | -15 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor days | 101 | 18 | 75 | 88 |
| Inventory days | 279 | 304 | 159 | 136 |
| Days payable | 354 | 114 | 31 | 11 |
| Cash conversion cycle | 26 | 208 | 202 | 213 |
| Working capital days | 9 | 7 | 129 | 196 |
| Return on capital employed | — | 42.3% | 57.6% | 27.7% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 73.48% as of Jun 2026; institutions cut 0.90 pts since Mar 2026.
- Promoters 73.48%
- Foreign institutions 1.08%
- Domestic institutions 6.10%
- Public 19.34%
Who is on the register
Named in the Jun 2026 filing
Every holder of Accretion Nutraveda Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 14.70% | unchanged | |
| 14.70% | unchanged | |
| 9.64% | unchanged | |
| 9.64% | unchanged | |
| 9.64% | unchanged | |
| 9.64% | unchanged | |
| AIF | 5.69% | −0.90 pp |
| 1.38% | unchanged | |
| 1.38% | unchanged | |
| 1.38% | unchanged | |
| 1.38% | unchanged | |
| 1.30% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Accretion Nutraveda Limited
Free account: one company. Everything above stays public.
Write why you follow Accretion Nutraveda Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Learn to analyse Accretion Nutraveda Limited
Guides on how to read this kind of business and the numbers that matter.